From Nasdaq.: 2025-02-23 19:33:53

Innovent Biologics Inc. announced that the NDA for ipilimumab injection has been accepted by China’s NMPA for neoadjuvant treatment of MSI-H/dMMR colon cancer with Priority Review designation. The NDA is based on Phase 3 trial results evaluating safety and efficacy of ipilimumab in combination with sintilimab, meeting primary endpoints of pathologic complete response rate and event-free survival. Interim analysis by the Independent Data Monitoring Committee confirmed the trial’s success. For more health news, visit rttnews.com.



Read more at Nasdaq.: NMPA Grants Priority Review To Innovent’s Ipilimumab Injection For Colon Cancer Treatment